메뉴 건너뛰기




Volumn 14, Issue 11, 2017, Pages 641-651

Direct-Acting antiviral agents for HCV infection affecting people who inject drugs

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; UNCLASSIFIED DRUG;

EID: 85032449652     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2017.106     Document Type: Review
Times cited : (124)

References (141)
  • 2
    • 80051676859 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews
    • Nelson, P. K. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378, 571-583 (2011).
    • (2011) Lancet , vol.378 , pp. 571-583
    • Nelson, P.K.1
  • 3
    • 67651083226 scopus 로고    scopus 로고
    • Hepatitis C treatment for injection drug users: A review of the available evidence
    • Hellard, M., Sacks-Davis, R. & Gold, J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clin. Infect. Dis. 49, 561-573 (2009).
    • (2009) Clin. Infect. Dis , vol.49 , pp. 561-573
    • Hellard, M.1    Sacks-Davis, R.2    Gold, J.3
  • 4
    • 84874781548 scopus 로고    scopus 로고
    • Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-Analysis
    • Dimova, R. B. et al. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-Analysis. Clin. Infect. Dis. 56, 806-816 (2013).
    • (2013) Clin. Infect. Dis , vol.56 , pp. 806-816
    • Dimova, R.B.1
  • 5
    • 84880984985 scopus 로고    scopus 로고
    • Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-Analysis
    • Aspinall, E. J. et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-Analysis. Clin. Infect. Dis. 57 (Suppl. 2), S80-S89 (2013).
    • (2013) Clin. Infect. Dis , vol.57 , pp. S80-S89
    • Aspinall, E.J.1
  • 6
    • 84941805183 scopus 로고    scopus 로고
    • Recommendations for the management of hepatitis C virus infection among people who inject drugs
    • Grebely, J. et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int. J. Drug Policy 26, 1028-1038 (2015).
    • (2015) Int. J. Drug Policy , vol.26 , pp. 1028-1038
    • Grebely, J.1
  • 7
    • 84905678530 scopus 로고    scopus 로고
    • Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents
    • Alavi, M. et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 34, 1198-1206 (2014).
    • (2014) Liver Int , vol.34 , pp. 1198-1206
    • Alavi, M.1
  • 8
    • 84892791410 scopus 로고    scopus 로고
    • Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011
    • Iversen, J. et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. J. Viral Hepat. 21, 198-207 (2014).
    • (2014) J. Viral Hepat , vol.21 , pp. 198-207
    • Iversen, J.1
  • 9
    • 84904987089 scopus 로고    scopus 로고
    • Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention
    • Wiessing, L. et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention. PLoS ONE 9, e103345 (2014).
    • (2014) PLoS ONE , vol.9 , pp. e103345
    • Wiessing, L.1
  • 10
    • 84941803970 scopus 로고    scopus 로고
    • Hepatitis C virus therapeutic development: In pursuit of perfectovir
    • Dore, G. J. & Feld, J. J. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". Clin. Infect. Dis. 60, 1829-1836 (2015).
    • (2015) Clin. Infect. Dis , vol.60 , pp. 1829-1836
    • Dore, G.J.1    Feld, J.J.2
  • 11
    • 84938795806 scopus 로고    scopus 로고
    • Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States
    • Barua, S. et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann. Intern. Med. 163, 215-223 (2015).
    • (2015) Ann. Intern. Med , vol.163 , pp. 215-223
    • Barua, S.1
  • 12
    • 84969850578 scopus 로고    scopus 로고
    • Clinicians' views of hepatitis C virus treatment candidacy with direct-Acting antiviral regimens for people who inject drugs
    • Asher, A. K. et al. Clinicians' views of hepatitis C virus treatment candidacy with direct-Acting antiviral regimens for people who inject drugs. Subst. Use Misuse 51, 1218-1223 (2016).
    • (2016) Subst. Use Misuse , vol.51 , pp. 1218-1223
    • Asher, A.K.1
  • 13
    • 84873586783 scopus 로고    scopus 로고
    • Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels
    • Grebely, J., Oser, M., Taylor, L. E. & Dore, G. J. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. J. Infect. Dis. 207 (Suppl. 1), S19-S25 (2013).
    • (2013) J. Infect. Dis , vol.207 , pp. S19-S25
    • Grebely, J.1    Oser, M.2    Taylor, L.E.3    Dore, G.J.4
  • 14
    • 84941811142 scopus 로고    scopus 로고
    • Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs
    • Larney, S. et al. Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. Int. J. Drug Policy 26, 950-957 (2015).
    • (2015) Int. J. Drug Policy , vol.26 , pp. 950-957
    • Larney, S.1
  • 17
    • 84880966007 scopus 로고    scopus 로고
    • Recommendations for the management of hepatitis C virus infection among people who inject drugs
    • Robaeys, G. et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin. Infect. Dis. 57 (Suppl. 2), S129-S137 (2013).
    • (2013) Clin. Infect. Dis , vol.57 , pp. S129-S137
    • Robaeys, G.1
  • 18
    • 9144251956 scopus 로고    scopus 로고
    • Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis
    • van Asten, L. et al. Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis. J. Infect. Dis. 189, 292-302 (2004).
    • (2004) J. Infect. Dis , vol.189 , pp. 292-302
    • Van Asten, L.1
  • 19
    • 79958698124 scopus 로고    scopus 로고
    • A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
    • Sievert, W. et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 31 (Suppl. 2), 61-80 (2011).
    • (2011) Liver Int , vol.31 , pp. 61-80
    • Sievert, W.1
  • 20
    • 56149097600 scopus 로고    scopus 로고
    • Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place
    • Hagan, H., Pouget, E. R., Des Jarlais, D. C. & Lelutiu-Weinberger, C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place. Am. J. Epidemiol. 168, 1099-1109 (2008).
    • (2008) Am. J. Epidemiol , vol.168 , pp. 1099-1109
    • Hagan, H.1    Pouget, E.R.2    Des Jarlais, D.C.3    Lelutiu-Weinberger, C.4
  • 21
    • 84880980513 scopus 로고    scopus 로고
    • Injection drug use and hepatitis C virus infection in young adult injectors: Using evidence to inform comprehensive prevention
    • Page, K., Morris, M. D., Hahn, J. A., Maher, L. & Prins, M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin. Infect. Dis. 57 (Suppl. 2), S32-S38 (2013).
    • (2013) Clin. Infect. Dis , vol.57 , pp. S32-S38
    • Page, K.1    Morris, M.D.2    Hahn, J.A.3    Maher, L.4    Prins, M.5
  • 22
    • 67349119488 scopus 로고    scopus 로고
    • Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience
    • 158-116
    • Roy, E., Boudreau, J. F. & Boivin, J. F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 102, 158-116 (2009).
    • (2009) Drug Alcohol Depend , vol.102
    • Roy, E.1    Boudreau, J.F.2    Boivin, J.F.3
  • 23
    • 84988358456 scopus 로고    scopus 로고
    • Viral evasion and challenges of hepatitis C virus vaccine development
    • Pierce, B. G., Keck, Z. Y. & Foung, S. K. Viral evasion and challenges of hepatitis C virus vaccine development. Curr. Opin. Virol. 20, 55-63 (2016).
    • (2016) Curr. Opin. Virol , vol.20 , pp. 55-63
    • Pierce, B.G.1    Keck, Z.Y.2    Foung, S.K.3
  • 24
    • 84908876253 scopus 로고    scopus 로고
    • A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
    • 261ra153
    • Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6, 261ra153 (2014).
    • (2014) Sci. Transl. Med , vol.6
    • Swadling, L.1
  • 25
    • 85032450350 scopus 로고    scopus 로고
    • US National Library of Medicine
    • US National Library of Medicine. ClinitralTrial.gov https://clinicaltrials.gov/ct2/show/NCT01436357 (2017).
    • (2017) ClinitralTrial.gov
  • 26
    • 84892955131 scopus 로고    scopus 로고
    • Interventions to prevent HIV and hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness
    • MacArthur, G. J. et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. Int. J. Drug Policy 25, 34-52 (2014).
    • (2014) Int. J. Drug Policy , vol.25 , pp. 34-52
    • MacArthur, G.J.1
  • 27
    • 77955057113 scopus 로고    scopus 로고
    • Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed
    • Degenhardt, L. et al. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376, 285-301 (2010).
    • (2010) Lancet , vol.376 , pp. 285-301
    • Degenhardt, L.1
  • 28
    • 79957930147 scopus 로고    scopus 로고
    • A systematic review and meta-Analysis of interventions to prevent hepatitis C virus infection in people who inject drugs
    • Hagan, H., Pouget, E. R. & Des Jarlais, D. C. A systematic review and meta-Analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J. Infect. Dis. 204, 74-83 (2011).
    • (2011) J. Infect. Dis , vol.204 , pp. 74-83
    • Hagan, H.1    Pouget, E.R.2    Des Jarlais, D.C.3
  • 29
    • 80053581086 scopus 로고    scopus 로고
    • The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence
    • Turner, K. M. et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106, 1978-1988 (2011).
    • (2011) Addiction , vol.106 , pp. 1978-1988
    • Turner, K.M.1
  • 30
    • 33947582096 scopus 로고    scopus 로고
    • Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users
    • van den Berg, C. H. et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur. J. Epidemiol. 22, 183-193 (2007).
    • (2007) Eur. J. Epidemiol , vol.22 , pp. 183-193
    • Van Den Berg, C.H.1
  • 31
    • 84920490123 scopus 로고    scopus 로고
    • The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users
    • Nolan, S. et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 109, 2053-2059 (2014).
    • (2014) Addiction , vol.109 , pp. 2053-2059
    • Nolan, S.1
  • 32
    • 84892987726 scopus 로고    scopus 로고
    • Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study
    • Aspinall, E. J. et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. Int. J. Drug Policy 25, 179-182 (2014).
    • (2014) Int. J. Drug Policy , vol.25 , pp. 179-182
    • Aspinall, E.J.1
  • 33
    • 84910017402 scopus 로고    scopus 로고
    • Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study
    • White, B., Dore, G. J., Lloyd, A. R., Rawlinson, W. D. & Maher, L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study. Med. J. Aust. 201, 326-329 (2014).
    • (2014) Med. J. Aust , vol.201 , pp. 326-329
    • White, B.1    Dore, G.J.2    Lloyd, A.R.3    Rawlinson, W.D.4    Maher, L.5
  • 34
    • 84919489681 scopus 로고    scopus 로고
    • Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users
    • Tsui, J. I., Evans, J. L., Lum, P. J., Hahn, J. A. & Page, K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern. Med. 174, 1974-1981 (2014).
    • (2014) JAMA Intern. Med , vol.174 , pp. 1974-1981
    • Tsui, J.I.1    Evans, J.L.2    Lum, P.J.3    Hahn, J.A.4    Page, K.5
  • 35
    • 79956066416 scopus 로고    scopus 로고
    • Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility
    • Martin, N. K. et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J. Hepatol. 54, 1137-1144 (2011).
    • (2011) J. Hepatol , vol.54 , pp. 1137-1144
    • Martin, N.K.1
  • 36
    • 84880998187 scopus 로고    scopus 로고
    • Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy
    • Martin, N. K., Hickman, M., Hutchinson, S. J., Goldberg, D. J. & Vickerman, P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin. Infect. Dis. 57 (Suppl. 2), S39-S45 (2013).
    • (2013) Clin. Infect. Dis , vol.57 , pp. S39-S45
    • Martin, N.K.1    Hickman, M.2    Hutchinson, S.J.3    Goldberg, D.J.4    Vickerman, P.5
  • 37
    • 84887020007 scopus 로고    scopus 로고
    • Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-Acting antivirals
    • Martin, N. K. et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-Acting antivirals. Hepatology 58, 1598-1609 (2013).
    • (2013) Hepatology , vol.58 , pp. 1598-1609
    • Martin, N.K.1
  • 38
    • 84929120243 scopus 로고    scopus 로고
    • Hepatitis C virus treatment as prevention among injecting drug users: Who should we cure first?
    • de Vos, A. S., Prins, M. & Kretzschmar, M. E. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? Addiction 110, 975-983 (2015).
    • (2015) Addiction , vol.110 , pp. 975-983
    • De Vos, A.S.1    Prins, M.2    Kretzschmar, M.E.3
  • 39
    • 84911929736 scopus 로고    scopus 로고
    • The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
    • Hellard, M. et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 60, 1861-1870 (2014).
    • (2014) Hepatology , vol.60 , pp. 1861-1870
    • Hellard, M.1
  • 40
    • 84919372737 scopus 로고    scopus 로고
    • Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis
    • Williams, R. et al. Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384, 1953-1997 (2014).
    • (2014) Lancet , vol.384 , pp. 1953-1997
    • Williams, R.1
  • 41
    • 84155180685 scopus 로고    scopus 로고
    • Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations
    • Martin, N. K. et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55, 49-57 (2012).
    • (2012) Hepatology , vol.55 , pp. 49-57
    • Martin, N.K.1
  • 42
    • 84964691873 scopus 로고    scopus 로고
    • Prioritization of HCV treatment in the direct-Acting antiviral era: An economic evaluation
    • Martin, N. K. et al. Prioritization of HCV treatment in the direct-Acting antiviral era: An economic evaluation. J. Hepatol. 65, 17-25 (2016).
    • (2016) J. Hepatol , vol.65 , pp. 17-25
    • Martin, N.K.1
  • 43
    • 85032443423 scopus 로고    scopus 로고
    • AASLD and IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C AASLD and IDSA
    • AASLD and IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA www.hcvguidelines.org (2015).
    • (2015)
  • 44
    • 84931560807 scopus 로고    scopus 로고
    • European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015
    • European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J. Hepatol, 63, 199-236 (2015).
    • (2015) J. Hepatol , vol.63 , pp. 199-236
  • 46
    • 84455182283 scopus 로고    scopus 로고
    • What is killing people with hepatitis C virus infection?
    • Grebely, J. & Dore, G. J. What is killing people with hepatitis C virus infection? Semin. Liver Dis. 31, 331-339 (2011).
    • (2011) Semin. Liver Dis , vol.31 , pp. 331-339
    • Grebely, J.1    Dore, G.J.2
  • 47
    • 84918817051 scopus 로고    scopus 로고
    • Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population
    • van der Meer, A. J. et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312, 1927-1928 (2014).
    • (2014) JAMA , vol.312 , pp. 1927-1928
    • Van Der Meer, A.J.1
  • 48
    • 84941810283 scopus 로고    scopus 로고
    • Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-Analysis
    • Smith, D. J., Combellick, J., Jordan, A. E. & Hagan, H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-Analysis. Int. J. Drug Policy 26, 911-921 (2015).
    • (2015) Int. J. Drug Policy , vol.26 , pp. 911-921
    • Smith, D.J.1    Combellick, J.2    Jordan, A.E.3    Hagan, H.4
  • 49
    • 84928227179 scopus 로고    scopus 로고
    • ABT-450/r/ombitasvir plus dasabuvir with or without ribavirin in HCV genotype 1-infected patients receiving stable opioid substitution treatment: Pooled analysis of efficacy and safety in phase 2 and phase 3 trials
    • Puoti, M. et al. ABT-450/r/ombitasvir plus dasabuvir with or without ribavirin in HCV genotype 1-infected patients receiving stable opioid substitution treatment: pooled analysis of efficacy and safety in phase 2 and phase 3 trials. Hepatology 60, 1135a-1136a (2014).
    • (2014) Hepatology , vol.60 , pp. 1135-1136
    • Puoti, M.1
  • 50
    • 84899068302 scopus 로고    scopus 로고
    • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
    • Feld, J. J. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1594-1603 (2014).
    • (2014) N. Engl. J. Med , vol.370 , pp. 1594-1603
    • Feld, J.J.1
  • 51
    • 84937064772 scopus 로고    scopus 로고
    • Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial
    • Zeuzem, S. et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann. Internal Med. 163, 1-13 (2015).
    • (2015) Ann. Internal Med , vol.163 , pp. 1-13
    • Zeuzem, S.1
  • 52
    • 85014946203 scopus 로고    scopus 로고
    • Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials
    • Grebely, J. et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials. Clin. Infect. Dis. 63, 1479-1481 (2016).
    • (2016) Clin. Infect. Dis , vol.63 , pp. 1479-1481
    • Grebely, J.1
  • 53
    • 85014883231 scopus 로고    scopus 로고
    • Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials
    • Grebely, J. et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials. Clin. Infect. Dis. 63, 1405-1411 (2016).
    • (2016) Clin. Infect. Dis , vol.63 , pp. 1405-1411
    • Grebely, J.1
  • 54
    • 85028743114 scopus 로고    scopus 로고
    • Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: A pooled analysis across 12 clinical trials [Abstract]
    • Grebely, J. et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: A pooled analysis across 12 clinical trials [Abstract]. J. Hepatol. 66 (Suppl.), S514 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S514
    • Grebely, J.1
  • 55
    • 85028767132 scopus 로고    scopus 로고
    • SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy [Abstract]
    • Grebely, J. et al. SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy [Abstract]. J. Hepatol. 66 (Suppl.), S513 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S513
    • Grebely, J.1
  • 57
    • 84940905515 scopus 로고    scopus 로고
    • Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
    • Lalezari, J. et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J. Hepatol. 63, 364-369 (2015).
    • (2015) J. Hepatol , vol.63 , pp. 364-369
    • Lalezari, J.1
  • 58
    • 85032431835 scopus 로고    scopus 로고
    • DAA-Treatment of HCV-infected patients on opioid substitution therapy (OST): Does the clinical setting matter? Data from the German hepatitis C-Registry (DHC-R
    • Christensen, S. et al. DAA-Treatment of HCV-infected patients on opioid substitution therapy (OST): does the clinical setting matter? Data from the german hepatitis C-Registry (DHC-R). Hepatology 64, 982A-983A (2016).
    • (2016) Hepatology , vol.64 , pp. 982A-983A
    • Christensen, S.1
  • 59
    • 84973320180 scopus 로고    scopus 로고
    • Direct observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-Threshold drug treatment facility-A new concept for treatment of patients with borderline compliance receiving opioid substitution therapy
    • Schötz, A., Moser, S., Marchart, K., Haltmayer, H. & Gschwantler, M. Direct observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-Threshold drug treatment facility-A new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am. J. Gastroenterol. 111, 903-905 (2016).
    • (2016) Am. J. Gastroenterol , vol.111 , pp. 903-905
    • Schötz, A.1    Moser, S.2    Marchart, K.3    Haltmayer, H.4    Gschwantler, M.5
  • 60
    • 85032444550 scopus 로고    scopus 로고
    • Direct-Acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: Real-life data
    • Scherz, N., Brunner, N. & Bruggmann, P. Direct-Acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data. J. Hepatol. 66, S726 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S726
    • Scherz, N.1    Brunner, N.2    Bruggmann, P.3
  • 61
    • 85032441293 scopus 로고    scopus 로고
    • Efficacy and safety of simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy [Abstract]
    • Dillon, J. et al. Efficacy and safety of simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy [Abstract]. J. Hepatol. 66, S520 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S520
    • Dillon, J.1
  • 62
    • 85032439697 scopus 로고    scopus 로고
    • Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy [Abstract]
    • Moser, S. et al. Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy [Abstract]. J. Hepatol. 66, S740 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S740
    • Moser, S.1
  • 63
    • 85032448134 scopus 로고    scopus 로고
    • Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone [Abstract]
    • Boyle, A. et al. Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone [Abstract]. J. Hepatol. 66, S282 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S282
    • Boyle, A.1
  • 64
    • 85032455140 scopus 로고    scopus 로고
    • High HCV Cure Rates for Drug Users Treated with DAAs at An Urban Primary Care Clinic
    • Norton, B. L. et al. High HCV cure rates for drug users treated with DAAs at an urban primary care clinic. Presented at Conference on Retroviruses and Opportunistic Infections.
    • Conference on Retroviruses and Opportunistic Infections
    • Norton, B.L.1
  • 65
    • 85017424283 scopus 로고    scopus 로고
    • Efficacy of all-oral HCV therapy in people who inject drugs [Abstract #1992]
    • 990A
    • Conway, B. et al. Efficacy of all-oral HCV therapy in people who inject drugs [Abstract #1992]. Hepatology 64, 990A (2016).
    • (2016) Hepatology , vol.64
    • Conway, B.1
  • 66
    • 85021824854 scopus 로고    scopus 로고
    • Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network
    • Morris, L. et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors' Health Network. Int. J. Drug Policy http://dx.doi.org/10.1016/j.drugpo.2017.05.056 (2017).
    • (2017) Int. J. Drug Policy
    • Morris, L.1
  • 67
    • 85020133598 scopus 로고    scopus 로고
    • Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting
    • Read, P. et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int. Drug Policy http://dx.doi.org/10.1016/j.drugpo.2017.05.032 (2017).
    • (2017) Int. Drug Policy
    • Read, P.1
  • 68
    • 85028824302 scopus 로고    scopus 로고
    • Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): The results of a prospective cohort study in Tbilisi
    • Bouscaillou, J. et al. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): The results of a prospective cohort study in Tbilisi, Georgia [Abstract[. J. Hepatol. 66, S409 (2017).
    • (2017) Georgia [Abstract[. J. Hepatol , vol.66 , pp. S409
    • Bouscaillou, J.1
  • 69
    • 85028872020 scopus 로고    scopus 로고
    • Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: The CHAMPS Study [Abstract]
    • Sulkowski, M. et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: The CHAMPS Study [Abstract]. J. Hepatol. 66, S719 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S719
    • Sulkowski, M.1
  • 70
    • 85020423456 scopus 로고    scopus 로고
    • Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence amongst people with a history of drug use at a community-based program in Toronto
    • Mason, K. et al. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence amongst people with a history of drug use at a community-based program in Toronto. Canada. Int. Drug Policy http://dx.doi.org/10.1016/j.drugpo.2017.05.02 (2017).
    • (2017) Canada. Int. Drug Policy
    • Mason, K.1
  • 71
    • 85018922173 scopus 로고    scopus 로고
    • Treatment with direct-Acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study
    • Boglione, L. et al. Treatment with direct-Acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. J. Viral Hepat. http://dx.doi.org/10.1111/jvh.12711 (2017).
    • (2017) J. Viral Hepat
    • Boglione, L.1
  • 72
    • 85028767132 scopus 로고    scopus 로고
    • Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study [Abstract]
    • Grebely, J. et al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study [Abstract]. J. Hepatol. 66, S513 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S513
    • Grebely, J.1
  • 74
    • 84960075820 scopus 로고    scopus 로고
    • Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-Analysis
    • Simmons, B., Saleem, J., Hill, A., Riley, R. D. & Cooke, G. S. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-Analysis. Clin. Infect dis 62, 683-694 (2016).
    • (2016) Clin. Infect Dis , vol.62 , pp. 683-694
    • Simmons, B.1    Saleem, J.2    Hill, A.3    Riley, R.D.4    Cooke, G.S.5
  • 75
    • 84963649635 scopus 로고    scopus 로고
    • Hepatitis C reinfection after sustained virological response
    • Midgard, H. et al. Hepatitis C reinfection after sustained virological response. J. Hepatol. 64, 1020-1026 (2016).
    • (2016) J. Hepatol , vol.64 , pp. 1020-1026
    • Midgard, H.1
  • 76
    • 84971596800 scopus 로고    scopus 로고
    • Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs
    • Weir, A. et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. Drug Alcohol Depend 165, 53-60 (2016).
    • (2016) Drug Alcohol Depend , vol.165 , pp. 53-60
    • Weir, A.1
  • 77
    • 84945476047 scopus 로고    scopus 로고
    • Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C
    • Pineda, J. A. et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J. Infect. 71, 571-577 (2015).
    • (2015) J. Infect , vol.71 , pp. 571-577
    • Pineda, J.A.1
  • 78
    • 84941811804 scopus 로고    scopus 로고
    • Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C
    • Alavi, M. et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Int. Drug Policy 26, 976-983 (2015).
    • (2015) Int. Drug Policy , vol.26 , pp. 976-983
    • Alavi, M.1
  • 79
    • 84881019269 scopus 로고    scopus 로고
    • Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection
    • Crawford, S. & Bath, N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clin. Infect dis 57 (Suppl. 2), S75-S79 (2013).
    • (2013) Clin. Infect Dis , vol.57 , pp. S75-S79
    • Crawford, S.1    Bath, N.2
  • 81
    • 84941811065 scopus 로고    scopus 로고
    • Hepatitis C transmission and treatment as prevention-The role of the injecting network
    • Hellard, M. et al. Hepatitis C transmission and treatment as prevention-The role of the injecting network. Int. Drug Policy 26, 958-962 (2015).
    • (2015) Int. Drug Policy , vol.26 , pp. 958-962
    • Hellard, M.1
  • 82
    • 77949540488 scopus 로고    scopus 로고
    • HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage
    • Mathers, B. M. et al. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 375, 1014-1028 (2010).
    • (2010) Lancet , vol.375 , pp. 1014-1028
    • Mathers, B.M.1
  • 83
    • 84894197245 scopus 로고    scopus 로고
    • Can hepatitis C virus infection be eradicated in people who inject drugs?
    • Grebely, J. & Dore, G. J. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 104, 62-72 (2014).
    • (2014) Antiviral Res , vol.104 , pp. 62-72
    • Grebely, J.1    Dore, G.J.2
  • 84
    • 84945351461 scopus 로고    scopus 로고
    • Historical epidemiology of hepatitis C virus (HCV select countries-volume 2
    • Saraswat, V. et al. Historical epidemiology of hepatitis C virus (HCV) in select countries-volume 2. J. Viral Hepatitis 22 (Suppl. 1), 6-25 (2015).
    • (2015) J. Viral Hepatitis , vol.22 , pp. 6-25
    • Saraswat, V.1
  • 85
    • 84945351461 scopus 로고    scopus 로고
    • Historical epidemiology of hepatitis C virus (HCV) select countries-volume 3
    • Liakina, V. et al. Historical epidemiology of hepatitis C virus (HCV) in select countries-volume 3. J. Viral Hepatitis 22 (Suppl. 4), 4-20 (2015).
    • (2015) J. Viral Hepatitis , vol.22 , pp. 4-20
    • Liakina, V.1
  • 86
    • 84904720839 scopus 로고    scopus 로고
    • Historical epidemiology of hepatitis C virus (HCV) in selected countries
    • Bruggmann, P. et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J. Viral Hepatitis 21 (Suppl. 1), 5-33 (2014).
    • (2014) J. Viral Hepatitis , vol.21 , pp. 5-33
    • Bruggmann, P.1
  • 87
    • 84995530829 scopus 로고    scopus 로고
    • Interventions to optimise the care continuum for chronic viral hepatitis: A systematic review and meta-Analyses
    • Zhou, K. et al. Interventions to optimise the care continuum for chronic viral hepatitis: A systematic review and meta-Analyses. Lancet Infect. Dis 16, 1409-1422 (2016).
    • (2016) Lancet Infect. Dis , vol.16 , pp. 1409-1422
    • Zhou, K.1
  • 88
    • 33750903205 scopus 로고    scopus 로고
    • Hepatitis C infection among injecting drug users in general practice: A cluster randomised controlled trial of clinical guidelines' implementation
    • Cullen, W. et al. Hepatitis C infection among injecting drug users in general practice: A cluster randomised controlled trial of clinical guidelines' implementation. Br. Pract. 56, 848-856 (2006).
    • (2006) Br. Pract , vol.56 , pp. 848-856
    • Cullen, W.1
  • 89
    • 85047688903 scopus 로고    scopus 로고
    • Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness
    • Rosenberg, S. D. et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatr. Serv. 61, 885-891 (2010).
    • (2010) Psychiatr. Serv , vol.61 , pp. 885-891
    • Rosenberg, S.D.1
  • 90
    • 79957853795 scopus 로고    scopus 로고
    • A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France
    • Sahajian, F. et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. J. Publ. Health 33, 182-192 (2011).
    • (2011) J. Publ. Health , vol.33 , pp. 182-192
    • Sahajian, F.1
  • 91
    • 34447512626 scopus 로고    scopus 로고
    • Hepatitis C in psychiatry inpatients: Testing rates, prevalence and risk behaviours
    • Lacey, C., Ellen, S., Devlin, H., Wright, E. & Mijch, A. Hepatitis C in psychiatry inpatients: Testing rates, prevalence and risk behaviours. Australas. Psychiatry 15, 315-319 (2007).
    • (2007) Australas. Psychiatry , vol.15 , pp. 315-319
    • Lacey, C.1    Ellen, S.2    Devlin, H.3    Wright, E.4    Mijch, A.5
  • 92
    • 84941807523 scopus 로고    scopus 로고
    • Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum
    • Meyer, J. P. et al. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. Int. Drug Policy 26, 922-935 (2015).
    • (2015) Int. Drug Policy , vol.26 , pp. 922-935
    • Meyer, J.P.1
  • 93
    • 85003831015 scopus 로고    scopus 로고
    • Evaluation of an electronic health record prompt for hepatitis c antibody screening of baby boomers in primary care-A cluster randomized control trial
    • Krauskopf, K. et al. Evaluation of an electronic health record prompt for hepatitis c antibody screening of baby boomers in primary care-A cluster randomized control trial. J. Gen. Intern. Med. 29, S88-S89 (2014).
    • (2014) J. Gen. Intern. Med , vol.29 , pp. S88-S89
    • Krauskopf, K.1
  • 94
    • 84860249270 scopus 로고    scopus 로고
    • Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk
    • Litwin, A. H. et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig. Liver dis 44, 497-503 (2012).
    • (2012) Dig. Liver Dis , vol.44 , pp. 497-503
    • Litwin, A.H.1
  • 95
    • 84867494768 scopus 로고    scopus 로고
    • Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting
    • Drainoni, M. L. et al. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am. Publ. Health 102, e115-e121 (2012).
    • (2012) Am. Publ. Health , vol.102 , pp. e115-e121
    • Drainoni, M.L.1
  • 96
    • 40149083761 scopus 로고    scopus 로고
    • Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial
    • Hickman, M. et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial. J. Viral Hepatitis 15, 250-254 (2008).
    • (2008) J. Viral Hepatitis , vol.15 , pp. 250-254
    • Hickman, M.1
  • 97
    • 84874401517 scopus 로고    scopus 로고
    • Hepatitis C testing in drug users using the dried blood spot test and the uptake of an innovative self-Administered DBS test
    • Abou-Saleh, M. T., Rice, P. & Foley, S. Hepatitis C testing in drug users using the dried blood spot test and the uptake of an innovative self-Administered DBS test. Addictive Disord. 12, 40-49 (2013).
    • (2013) Addictive Disord , vol.12 , pp. 40-49
    • Abou-Saleh, M.T.1    Rice, P.2    Foley, S.3
  • 98
    • 84976454908 scopus 로고    scopus 로고
    • Dry blood spot testing for hepatitis C in people who injected drugs: Reaching the populations other tests cannot reach
    • Tait, J. M., Stephens, B. P., McIntyre, P., Evans, M. & Dillon, J. F. Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach. J. Hepatol. 58, S204-S204 (2013).
    • (2013) J. Hepatol , vol.58 , pp. S204-S204
    • Tait, J.M.1    Stephens, B.P.2    McIntyre, P.3    Evans, M.4    Dillon, J.F.5
  • 99
    • 60349108525 scopus 로고    scopus 로고
    • Improving blood-borne viral diagnosis; Clinical audit of the uptake of dried blood spot testing offered by a substance misuse service
    • Craine, N., Parry, J., O'Toole, J., D'Arcy, S. & Lyons, M. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. J. Viral Hepatitis 16, 219-222 (2009).
    • (2009) J. Viral Hepatitis , vol.16 , pp. 219-222
    • Craine, N.1    Parry, J.2    O'Toole, J.3    D'Arcy, S.4    Lyons, M.5
  • 100
    • 84911123627 scopus 로고    scopus 로고
    • Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing
    • McLeod, A. et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. J. Epidemiol. Commun. Health 68, 1182-1188 (2014).
    • (2014) J. Epidemiol. Commun. Health , vol.68 , pp. 1182-1188
    • McLeod, A.1
  • 101
    • 84942200209 scopus 로고    scopus 로고
    • The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature
    • Coats, J. T. & Dillon, J. F. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature. Int. Drug Policy 26, 1050-1055 (2015).
    • (2015) Int. Drug Policy , vol.26 , pp. 1050-1055
    • Coats, J.T.1    Dillon, J.F.2
  • 102
    • 84918770521 scopus 로고    scopus 로고
    • Strategies for hepatitis C testing and linkage to care for vulnerable populations: Point-of-care and standard HCV testing in a mobile medical clinic
    • Morano, J. P. et al. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J. Commun. Health 39, 922-934 (2014).
    • (2014) J. Commun. Health , vol.39 , pp. 922-934
    • Morano, J.P.1
  • 103
    • 85014273615 scopus 로고    scopus 로고
    • Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-To-care: Results of a randomized control trial in persons without healthcare coverage
    • Bottero, J. et al. Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-To-care: results of a randomized control trial in persons without healthcare coverage. Open Forum Infect. Dis. 2, ofv162 (2015).
    • (2015) Open Forum Infect. Dis , vol.2 , pp. ofv162
    • Bottero, J.1
  • 104
    • 85007137332 scopus 로고    scopus 로고
    • A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections
    • Beckwith, C. G. et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. J. Publ. Health 38, 130-137 (2016).
    • (2016) J. Publ. Health , vol.38 , pp. 130-137
    • Beckwith, C.G.1
  • 105
    • 85032436446 scopus 로고    scopus 로고
    • Terrence Higgins Trust FASTEST direct. Terrence Higgins Trust
    • Terrence Higgins Trust. FASTEST direct. Terrence Higgins Trust https://www.tht.org.uk/sexual-health/About-HIV/HIV-postal-Test (2016).
    • (2016)
  • 106
    • 84897583623 scopus 로고    scopus 로고
    • Targeted hepatitis C screening among ex-injection drug users in the community
    • Wong, V. W. et al. Targeted hepatitis C screening among ex-injection drug users in the community. J. Gastroenterol. Hepatol. 29, 116-120 (2014).
    • (2014) J. Gastroenterol. Hepatol , vol.29 , pp. 116-120
    • Wong, V.W.1
  • 107
    • 84861699122 scopus 로고    scopus 로고
    • Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA
    • Jewett, A. et al. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. J. Clin. Virol. 54, 213-217 (2012).
    • (2012) J. Clin. Virol , vol.54 , pp. 213-217
    • Jewett, A.1
  • 108
    • 80052235417 scopus 로고    scopus 로고
    • Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus
    • Smith, B. D. et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J. Infect. Dis. 204, 825-831 (2011).
    • (2011) J. Infect. Dis , vol.204 , pp. 825-831
    • Smith, B.D.1
  • 109
    • 80052897317 scopus 로고    scopus 로고
    • Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites
    • Smith, B. D. et al. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin. Infect. Dis. 53, 780-786 (2011).
    • (2011) Clin. Infect. Dis , vol.53 , pp. 780-786
    • Smith, B.D.1
  • 110
    • 80055005438 scopus 로고    scopus 로고
    • Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations
    • Drobnik, A. et al. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am. Publ. Health 101, 2151-2155 (2011).
    • (2011) Am. Publ. Health , vol.101 , pp. 2151-2155
    • Drobnik, A.1
  • 111
    • 84894634227 scopus 로고    scopus 로고
    • The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
    • Grebely, J. et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59, 109-120 (2014).
    • (2014) Hepatology , vol.59 , pp. 109-120
    • Grebely, J.1
  • 113
    • 85020535343 scopus 로고    scopus 로고
    • Evaluation of the Xpert® HCV viral load point-of-care assay from venipuncture-collected and finger-stick capillary whole-blood samples: A prospective study
    • Grebely, J. et al. Evaluation of the Xpert® HCV viral load point-of-care assay from venipuncture-collected and finger-stick capillary whole-blood samples: A prospective study. Lancet Gastro Hepatol. 2, 514-520 (2017).
    • (2017) Lancet Gastro Hepatol , vol.2 , pp. 514-520
    • Grebely, J.1
  • 114
    • 84985963194 scopus 로고    scopus 로고
    • Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: A systematic review and meta-Analysis
    • Freiman, J. M. et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: A systematic review and meta-Analysis. Ann. Intern. med. 165, 345-355 (2016).
    • (2016) Ann. Intern. Med , vol.165 , pp. 345-355
    • Freiman, J.M.1
  • 115
    • 84942912048 scopus 로고    scopus 로고
    • Simplified diagnostic monitoring for hepatitis C, in the new era of direct-Acting antiviral treatment
    • Cohn, J., Roberts, T., Amorosa, V., Lemoine, M. & Hill, A. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-Acting antiviral treatment. Curr. Opin. HIV AIDS 10, 369-373 (2015).
    • (2015) Curr. Opin. HIV AIDS , vol.10 , pp. 369-373
    • Cohn, J.1    Roberts, T.2    Amorosa, V.3    Lemoine, M.4    Hill, A.5
  • 116
    • 84908507517 scopus 로고    scopus 로고
    • Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland
    • McAllister, G. et al. Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. J. Clin. Virol. 61, 359-364 (2014).
    • (2014) J. Clin. Virol , vol.61 , pp. 359-364
    • McAllister, G.1
  • 117
    • 79953790732 scopus 로고    scopus 로고
    • Outreach screening of drug users for cirrhosis with transient elastography
    • Moessner, B. K. et al. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 106, 970-976 (2011).
    • (2011) Addiction , vol.106 , pp. 970-976
    • Moessner, B.K.1
  • 118
    • 59149104257 scopus 로고    scopus 로고
    • FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: A prospective study
    • Foucher, J. et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: A prospective study. J. Viral Hepatitis 16, 121-131 (2009).
    • (2009) J. Viral Hepatitis , vol.16 , pp. 121-131
    • Foucher, J.1
  • 119
    • 84941808913 scopus 로고    scopus 로고
    • Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study
    • Marshall, A. D. et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Int. Drug Policy 26, 984-991 (2015).
    • (2015) Int. Drug Policy , vol.26 , pp. 984-991
    • Marshall, A.D.1
  • 120
    • 84879781393 scopus 로고    scopus 로고
    • A randomized trial of a hepatitis care coordination model in methadone maintenance treatment
    • Masson, C. L. et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am. Publ. Health 103, E81-E88 (2013).
    • (2013) Am. Publ. Health , vol.103 , pp. E81-E88
    • Masson, C.L.1
  • 121
    • 80053894219 scopus 로고    scopus 로고
    • A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment
    • Evon, D. M. et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am. Gastroenterol. 106, 1777-1786 (2011).
    • (2011) Am. Gastroenterol , vol.106 , pp. 1777-1786
    • Evon, D.M.1
  • 122
    • 33749162949 scopus 로고    scopus 로고
    • Integrated psychiatric/medical care in a chronic hepatitis C clinic: Effect on antiviral treatment evaluation and outcomes
    • Knott, A. et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am. Gastroenterol. 101, 2254-2262 (2006).
    • (2006) Am. Gastroenterol , vol.101 , pp. 2254-2262
    • Knott, A.1
  • 123
    • 84944279905 scopus 로고    scopus 로고
    • Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse
    • Ho, S. B. et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin. Gastroenterol. Hepatol. 13, 2005-2014e3 (2015).
    • (2015) Clin. Gastroenterol. Hepatol , vol.13 , pp. 2005-2014e3
    • Ho, S.B.1
  • 124
    • 84931560419 scopus 로고    scopus 로고
    • Results from a geographically focused, community-based HCV screening, linkage-To-care and patient navigation program
    • Trooskin, S. B. et al. Results from a geographically focused, community-based HCV screening, linkage-To-care and patient navigation program. J. Gen. Intern. Med. 30, 950-957 (2015).
    • (2015) J. Gen. Intern. Med , vol.30 , pp. 950-957
    • Trooskin, S.B.1
  • 125
    • 84959176541 scopus 로고    scopus 로고
    • Public health clinic-based hepatitis C testing and linkage to care in Baltimore
    • Falade-Nwulia, O. et al. Public health clinic-based hepatitis C testing and linkage to care in baltimore. J. Viral Hepatitis 23, 366-374 (2016).
    • (2016) J. Viral Hepatitis , vol.23 , pp. 366-374
    • Falade-Nwulia, O.1
  • 126
    • 84881004592 scopus 로고    scopus 로고
    • Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all
    • Bruggmann, P. & Litwin, A. H. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin. Infect. Dis. 57 (Suppl. 2), S56-S61 (2013).
    • (2013) Clin. Infect. Dis , vol.57 , pp. S56-S61
    • Bruggmann, P.1    Litwin, A.H.2
  • 127
    • 84959124779 scopus 로고    scopus 로고
    • Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-Analysis
    • Platt, L. et al. Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-Analysis. Lancet Infect dis 16, 797-808 (2016).
    • (2016) Lancet Infect Dis , vol.16 , pp. 797-808
    • Platt, L.1
  • 128
    • 84941942912 scopus 로고    scopus 로고
    • Excluding people who use drugs or alcohol from access to hepatitis C treatments-Is this fair, given the available data?
    • Grebely, J. et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments-Is this fair, given the available data? J. Hepatol. 63, 779-782 (2015).
    • (2015) J. Hepatol , vol.63 , pp. 779-782
    • Grebely, J.1
  • 129
    • 85012204727 scopus 로고    scopus 로고
    • A review of restrictions for reimbursement of direct-Acting antiviral treatment for hepatitis C virus infection in Canada
    • Marshall, A. D. et al. A review of restrictions for reimbursement of direct-Acting antiviral treatment for hepatitis C virus infection in Canada. CMAJ Open 4, E605-E614 (2016).
    • (2016) CMAJ Open , vol.4 , pp. E605-E614
    • Marshall, A.D.1
  • 130
    • 85032445154 scopus 로고    scopus 로고
    • Medicaid private insurers begin to lift curbs on pricey hepatitis C drugs
    • Graham, J. Medicaid, private insurers begin to lift curbs on pricey hepatitis C drugs. Kaiser Health News http://khn.org/news/medicaid-private-insurers-begin-To-lift-curbs-on-pricey-hepatitis-c-drugs/(2016).
    • (2016) Kaiser Health News
    • Graham, J.1
  • 132
    • 85020580312 scopus 로고    scopus 로고
    • Judge orders Washington medicaid to provide lifesaving hepatitis c drugs for all
    • Aleccia, J. Judge orders Washington Medicaid to provide lifesaving hepatitis C drugs for all. The Seattle Times http://www.seattletimes.com/seattle-news/health/judge-orders-Apple-health-To-cover-hepatitis-c-drugs-for-All/(2016).
    • (2016) The Seattle Times
    • Aleccia, J.1
  • 134
    • 84941809284 scopus 로고    scopus 로고
    • Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle
    • Keats, J. et al. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle. Australia. Int. Drug Policy 26, 999-1006 (2015).
    • (2015) Australia. Int. Drug Policy , vol.26 , pp. 999-1006
    • Keats, J.1
  • 135
    • 79955871966 scopus 로고    scopus 로고
    • Physicians' attitudes and practice toward treating injection drug users with hepatitis C: Results from a national specialist survey in Canada
    • Myles, A., Mugford, G. J., Zhao, J., Krahn, M. & Wang, P. P. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can. Gastroenterol. 25, 135-139 (2011).
    • (2011) Can. Gastroenterol , vol.25 , pp. 135-139
    • Myles, A.1    Mugford, G.J.2    Zhao, J.3    Krahn, M.4    Wang, P.P.5
  • 136
    • 80052516394 scopus 로고    scopus 로고
    • General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting
    • Lambert, S. M. et al. General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting. Aust. Prim. Health 17, 282-287 (2011).
    • (2011) Aust. Prim. Health , vol.17 , pp. 282-287
    • Lambert, S.M.1
  • 138
    • 84986325924 scopus 로고    scopus 로고
    • Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees
    • Dolan, K. et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 388, 1089-1102 (2016).
    • (2016) Lancet , vol.388 , pp. 1089-1102
    • Dolan, K.1
  • 139
    • 84992364799 scopus 로고    scopus 로고
    • The perfect storm: Incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
    • Altice, F. L. et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet 388, 1228-1248 (2016).
    • (2016) Lancet , vol.388 , pp. 1228-1248
    • Altice, F.L.1
  • 140
    • 85012255109 scopus 로고    scopus 로고
    • Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
    • Butner, J. L. et al. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J. Subst. Abuse Treat. 75, 49-53 (2017).
    • J. Subst. Abuse Treat , vol.75 , Issue.49-53 , pp. 2017
    • Butner, J.L.1
  • 141
    • 85032439231 scopus 로고    scopus 로고
    • The PREVAIL Study: Intensive models of HCV care for people who inject drugs
    • Litwin, A. H. et al. The PREVAIL Study: intensive models of HCV care for people who inject drugs J. Hepatol. 66, S72 (2017).
    • (2017) J. Hepatol , vol.66 , pp. S72
    • Litwin, A.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.